Clinical Trials
16 trialsNCT05994001 2026-02-18
Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody
Shanghai Zhongshan Hospital
Phase 1/2 Active not recruiting
NCT03785873 2026-02-13
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT06548412 2026-01-20
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04203160 2025-12-31
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
NCT07269158 2025-12-08
A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
Yonsei University
Phase 1/2 Not yet recruiting
NCT05052099 2025-09-29
COMBATBIL
University Hospital, Essen
Phase 1/2 Completed
NCT06255262 2024-02-13
Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
China Medical University, China
Phase 1/2 Unknown
NCT06074029 2024-02-08
Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT03475953 2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2 Unknown
NCT05742750 2023-02-24
A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT05327582 2022-04-14
An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT02992340 2021-01-14
Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC
ASLAN Pharmaceuticals
Phase 1/2 Terminated
NCT02773459 2019-09-30
MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer
Seoul National University Hospital
Phase 1/2 Completed
NCT04004234 2019-07-09
A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT00955721 2018-01-03
A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer
University of Miami
Phase 1/2 Terminated
NCT03311789 2017-10-17
Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs
Chinese PLA General Hospital
Phase 1/2 Unknown